Cargando…
Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists
[Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956242/ https://www.ncbi.nlm.nih.gov/pubmed/31821760 http://dx.doi.org/10.1021/acs.jmedchem.9b01372 |
_version_ | 1783487115408965632 |
---|---|
author | Meijer, Femke A. Doveston, Richard G. de Vries, Rens M.J.M. Vos, Gaël M. Vos, Alex A.A. Leysen, Seppe Scheepstra, Marcel Ottmann, Christian Milroy, Lech-Gustav Brunsveld, Luc |
author_facet | Meijer, Femke A. Doveston, Richard G. de Vries, Rens M.J.M. Vos, Gaël M. Vos, Alex A.A. Leysen, Seppe Scheepstra, Marcel Ottmann, Christian Milroy, Lech-Gustav Brunsveld, Luc |
author_sort | Meijer, Femke A. |
collection | PubMed |
description | [Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric inhibition. Here, we report a highly efficient in silico-guided approach that led to the discovery of novel allosteric RORγt inverse agonists with a distinct isoxazole chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment assay and effectively reduced IL-17a mRNA production in EL4 cells, a marker of RORγt activity. The projected allosteric mode of action of 25 was confirmed by biochemical experiments and cocrystallization with the RORγt ligand binding domain. The isoxazole compounds have promising pharmacokinetic properties comparable to other allosteric ligands but with a more diverse chemotype. The efficient ligand-based design approach adopted demonstrates its versatility in generating chemical diversity for allosteric targeting of RORγt. |
format | Online Article Text |
id | pubmed-6956242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-69562422020-01-14 Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists Meijer, Femke A. Doveston, Richard G. de Vries, Rens M.J.M. Vos, Gaël M. Vos, Alex A.A. Leysen, Seppe Scheepstra, Marcel Ottmann, Christian Milroy, Lech-Gustav Brunsveld, Luc J Med Chem [Image: see text] Retinoic acid receptor-related orphan receptor γt (RORγt) is a nuclear receptor associated with the pathogenesis of autoimmune diseases. Allosteric inhibition of RORγt is conceptually new, unique for this specific nuclear receptor, and offers advantages over traditional orthosteric inhibition. Here, we report a highly efficient in silico-guided approach that led to the discovery of novel allosteric RORγt inverse agonists with a distinct isoxazole chemotype. The the most potent compound, 25 (FM26), displayed submicromolar inhibition in a coactivator recruitment assay and effectively reduced IL-17a mRNA production in EL4 cells, a marker of RORγt activity. The projected allosteric mode of action of 25 was confirmed by biochemical experiments and cocrystallization with the RORγt ligand binding domain. The isoxazole compounds have promising pharmacokinetic properties comparable to other allosteric ligands but with a more diverse chemotype. The efficient ligand-based design approach adopted demonstrates its versatility in generating chemical diversity for allosteric targeting of RORγt. American Chemical Society 2019-12-10 2020-01-09 /pmc/articles/PMC6956242/ /pubmed/31821760 http://dx.doi.org/10.1021/acs.jmedchem.9b01372 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Non-Commercial No Derivative Works (CC-BY-NC-ND) Attribution License (http://pubs.acs.org/page/policy/authorchoice_ccbyncnd_termsofuse.html) , which permits copying and redistribution of the article, and creation of adaptations, all for non-commercial purposes. |
spellingShingle | Meijer, Femke A. Doveston, Richard G. de Vries, Rens M.J.M. Vos, Gaël M. Vos, Alex A.A. Leysen, Seppe Scheepstra, Marcel Ottmann, Christian Milroy, Lech-Gustav Brunsveld, Luc Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists |
title | Ligand-Based
Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor
γt (RORγt) Inverse Agonists |
title_full | Ligand-Based
Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor
γt (RORγt) Inverse Agonists |
title_fullStr | Ligand-Based
Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor
γt (RORγt) Inverse Agonists |
title_full_unstemmed | Ligand-Based
Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor
γt (RORγt) Inverse Agonists |
title_short | Ligand-Based
Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor
γt (RORγt) Inverse Agonists |
title_sort | ligand-based
design of allosteric retinoic acid receptor-related orphan receptor
γt (rorγt) inverse agonists |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956242/ https://www.ncbi.nlm.nih.gov/pubmed/31821760 http://dx.doi.org/10.1021/acs.jmedchem.9b01372 |
work_keys_str_mv | AT meijerfemkea ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT dovestonrichardg ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT devriesrensmjm ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT vosgaelm ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT vosalexaa ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT leysenseppe ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT scheepstramarcel ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT ottmannchristian ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT milroylechgustav ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists AT brunsveldluc ligandbaseddesignofallostericretinoicacidreceptorrelatedorphanreceptorgtrorgtinverseagonists |